摘要
目的 研究治疗剂量下4种抗结核药物(异烟肼、左氧氟沙星、乙胺丁醇、吡嗪酰胺对Caco-2细胞上P-糖蛋白功能、表达及MDR1 mRNA表达的影响，从而解释联合抗痨治疗中不同组合的合理性。方法 采用流式细胞仪测定细胞内罗丹明-123的浓度，考察药物对P-糖蛋白功能的影响，流式细胞术分析药物对Caco-2细胞上P-糖蛋白表达的影响，实时荧光定量PCR技术分析药物对Caco-2细胞MDR1基因mRNA水平表达的影响。结果 含药培养20 d后，异烟肼和乙胺丁醇减少了罗丹明-123在Caco-2细胞内的蓄积(P＜0.05，为诱导作用；异烟肼、乙胺丁醇均上调了Caco-2细胞上P-糖蛋白的表达(P＜0.05，其P-糖蛋白表达量分别为阴性对照组的3.5和3.8倍；同时上调了Caco-2细胞上MDR1 mRNA的表达(P＜0.05，其MDR1 mRNA的表达量分别为阴性对照组的11.5和11倍。左氧氟沙星增加了罗丹明-123在Caco-2细胞内的蓄积(P＜0.05，为抑制作用；下调了Caco-2细胞上P-糖蛋白和MDR1 mRNA的表达(P＜0.05，其P-糖蛋白和MDR1 mRNA表达量分别为阴性对照组的50%和32%。而吡嗪酰胺与P-糖蛋白无明显相互作用。结论 治疗剂量的异烟肼和乙胺丁醇为P-糖蛋白的诱导剂，左氧氟沙星为P-糖蛋白的抑制剂，而吡嗪酰胺对P-糖蛋白功能和表达无明显影响。
Abstract
OBJECTIVE To study the effects of four anti-tuberculosis drugs on the function and expression of P-glycoprotein and the MDR1 mRNA expression， for explaining the rationality of different combination in anti-tuberculosis chemotherapy. METHODS The effect of the drugs on P-glycoprotein function was analyzed using Rh-123 assay. The flow cytometry was used to determine the intracellular Rh-123 concentration and the expression of P-glycoprotein in Caco-2 cells. Real-time fluorescent quantitative polymerase chain reaction was used to measure the expression of MDR1 gene mRNA in Caco-2 cells. RESULTS After the intervention for 20 d， the therapeutic doses of isoniazid and ethambutol decreased the accumulation of rhodamine123 in Caco-2 cells significantly compared with that of negative control group (P<0.05. The therapeutic doses of isoniazid and ethambutol both up-regulated the cellular P-glycoprotein protein and MDR1 mRNA expression levels (P<0.05. Compared with the controls， the total quantity of P-glycoprotein were 3.5 and 3.8 folds higher than that of controls， and the total levels of MDR1 mRNA expression were 11.5 and 11 folds higher than that of controls， respectively. Therapeutic doses of levofloxacin increased the accumulation of rhodamine123 in Caco-2 cells significantly higher than that of negative control group (P<0.05. The therapeutic doses of levofloxacin down-regulated the cellular P-glycoprotein protein and MDR1 mRNA expression levels (P<0.05. Compared with the controls， the total levels of P-glycoprotein and MDR1 mRNA expression were 50% and 32% of controls， respectively. Pyrazinamide showed no significant interaction with P-glycoprotein. CONCLUSION Therapeutic doses of isoniazid and ethambutol might be inducer of P-glycoprotein， levofloxacin might be inhibitors of p-glycoprotein， and pyrazinamide showed no significant interaction with P-glycoprotein.
关键词
抗结核药物 /
P-糖蛋白 /
Caco-2细胞 /
MDR1基因 /
异烟肼 /
左氧氟沙星 /
乙胺丁醇 /
吡嗪酰胺
{{custom_keyword}} /
Key words
anti-tuberculosis drugs /
P-glycoprotein /
Caco-2 cells /
MDR1 /
isoniazid /
levofloxacin /
ethambutol /
pyrazinamide
{{custom_keyword}} /
方平飞 高维 李焕德 刘艺平.
治疗剂量下4种抗结核药物与Caco-2细胞上P-gp相互作用研究[J]. 中国药学杂志, 2011, 46(1): 48-53
FNG Ping-fei;GO Wei;LI Hun-de;LIU Yi-ping.
Initial Study on Interaction between Therapeutic Doses of Four Anti-Tuberculosis Drugs and P-Glycoprotein in Caco-2 Cells[J]. Chinese Pharmaceutical Journal, 2011, 46(1): 48-53
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] ZHANG L X， TU D H， HE D X，et al. Risk of tuberculosis infection and tuberculous meningitis after discontinuation of bacillus calmette-Guerin in Beijing[J]. Am J Respir Crit Care Med，2000，162(12： 1314-1317.
[2] Buccetin of Chinese Antituberculosis Assoclation. The recommendation of chemotherepy in MDR-TB [J]. Chin J Antituberc Assoc（中国防痨杂志，2003， 25(1：4-9.
[3] MARZOLINI C， PAUS E， BUCLIN T， et al. Polymorphsims in human MDR1 (P-glycoprotein： recent advances and clinical relevance [J]. Clin Pharmacol Ther，2004，75(1：13-33.
[4] GOTTESMAN M M， FOJO T， BATES S E. Multidrug resistance in cancer： role of ATP-dependent transporters[J]. Nat Rev Cancer，2002，2(4： 48-58.
[5] CALATOZZOLO C， GELATI M， CIUSANI E， et al. Expression of drug resistance proteins P-gp， MRP1， MRP3， MRP5 and GST-pi in human glioma [J]. J Neurooncol， 2005， 74(2：113-121.
[6] VILCHEZE C， MORBIDONI H R， WEISBROD T R， et al. Inactivation of the inhA -encoded fatty acid synthase II (FASII enoyl-acyl carrier protein reductase induces accumulation of the FASI end products and cells lysis of Mycobacteriumsmegmatis [J]. J Bacteriol， 2000， 182(14： 4059-4067.
[7] GREINER B， EICHELBAUM M， FRITZ P， et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin [J]. J Clin Invest，1999，104(2：147-153.
[8] GURLEY B J， SWAIN A， WILLIAMS D K， et al. Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions： Comparative effects of St. John's wort， Echinacea， clarithromycin， and rifampin on digoxin pharmacokinetics[J]. Mol Nutr Food Res， 2008， 52（7：722-779.
[9] ZONG J， POLLACK G M. Modulation of P-glycoprotein transport activity in the mouse blood-brain barrier by rifampin [J]. J Pharmacol Exp Ther， 2003，306(2：556-562.
[10] SIKRI V， PAL D， JAIN R， et al. Cotransport of macrolide and fluoroquinolones， a beneficial interaction reversing P-glycoprotein efflux[J]. Am J Ther， 2004， 11(6：433-442.
[11] SHIRASAKA Y， KAWASAKI M， SAKANE T， et al. Induction of human P-glycoprotein in Caco-2 cells： development of a highly sensitive assay system for P-glycoprotein-mediated drug transport [J]. Drug Metab Pharmacokinet，2006，21(5：414-423.
[12] SONG J， LIU X L， HE J，et al. Effects of tetramethylpyrazine and ginsenoside Rg1 on p-glycoprotein function and expression in caco-2 cells[J]. Chin Pharm J（中国药学杂志，2008，43(13：987-991.
[13] KATRIEN S， BARBARA D M， CATHARINA D， et al. Comparison of two functional flow cytometric assays to assess P-gp activity in acute leukemia [J]. Leukemia and Lymphoma，2004，11(45：2221-2228.
[14] SCHIEDLMEIER B， KHLCKE K， ECKERT H G， et al. Quantitative assessment of retroviral transfer of the human multidrug resistance 1 gene to human mobilized peripheral blood progenitor cells engrafted in nonobese diabetic/severe combined immunodeficient mice [J]. Blood， 2000，95(4：1237-1248.
[15] HASLAM I S， JONES K， COLEMAN T， et al. Induction of P-glycoprotein expression and function in human intestinal epithelial cells (T84 [J]. Biochem Pharmacol，2008，76(7：850-861.
[16] SCHEFFER G L， PIJNENBORG A C， SMIT E F， et al. Multidrug resistance related molecules in human and murine lung [J]. J Clin Pathol， 2002， 55(5：332-339.
[17] JIN S， GORFAJN B， FAIRCLOTH G， et al. Ecteinascidin 743， atranscription-targeted chemotherapeutic that inhibits MDR1 activation [J]. Proc Natl Acad Sci USA， 2000， 97(6： 6775-6779.
[18] HASLAM I S， JONES K， COLEMAN T， et al. Rifampin and digoxin induction of MDR1 expression and function in human intestinal (T84 epithelial cells[J]. Br J Pharmacol，2008，154(1：246-255.
[19] HARTKOORN R C， CHANDLER B， OWEN A. Differential drug susceptibility of intracellular and extracellular tuberculosis， and the impact of P-glycoprotein[J]. Tuberculosis，2007，87(3： 248-255.
[20] LIU D Y， YANG M， ZHU H J， et al. Human pregnane X receptor-mediated transcriptional regulation of cytochrome P450 3A4 by some phytochemicals [J]. J Zhejiang Univ (Med Sci（浙江大学学报：医学版， 2006， 35 (1： 8-13.
[21] KIIEWER S A. The nuclear pregnane X. receptor regulates xenobiotic detoxification [J]. J Nutr，2003， 133(7：2444-2447.
[22] WATKINS R E， NOBLE S M， REDINBO M R. Structural insights into the promiscuity and function of the human pregnane X receptor [J]. Curr Opin Drug Discov Devel，2002，5(1：150-158.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(993 KB)
